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Invasive pulmonary aspergdlosis (IPA) occurs mostly in immunocompromised hosts and especially in 
neutropenic patients. Improved prognosis for IPA requires early hagnosis. We report our experience in the 
management of IPA in patients with hematological mahgnancies. In prolonged neutropenia (> 10 days), 
thoracic CT scanning seems to be the best choice for the diagnosis of IPA (with CT halo or air-crescent signs). 
Its systematic use allows a dramatic reduction in the time to achieve the diagnosis, if there is evidence of a halo 
sign. The systematic screening for the detection of Aspergillus antigenemia with an ELISA test is helpful for 
early diagnosis. The detection of Aspergillus antigen (with the less sensitive latex agglutination test) on 
bronchoalveolar lavage PAL) fluid may also be as useful. The treatment of IPA relies on amphotericin B (or its 
lipid formulations) or on azole antifungal agents. Pulmonary surgical resection should be considered either as 
an emergency procedure (despite persistent neutropenia) to avoid massive hemoptysis, or as an elective or 
diagnostic procedure. This global strategy for the management of IPA is associated with a 75-80% success rate 
in hematological patients. Nevertheless, the control of underlying malignancy remains a major prognostic 
factor. 
Clin Microbiol Infect 2001: 7 (Supplement 2): 54-61 
INTRODU CTlON 
Invasive aspergillosis remains a life-threatening complica- 
tion in immunocompromised patients, especially in neu- 
tropenic patients, and its incidence has increased in such 
paoents during the past two decades [l-31. The prognosis 
remains poor in leukemic patients, despite amphotericin B 
( A d )  treatment. The mortality rate reaches 60-65% when 
invasive pulmonary aspergillosis (IPA) occurs during 
chemotherapy-induced neutropenia and could exceed 
90% in the setting of allogenic bone marrow transplantation 
(BMT) [4,5). IPA is the most common form (> 80-90% of 
cases) of the disease, especially in neutropenic patients 
I5,6]. Some reports demonstrate that early recognition of 
IPA and prompt antifungal treatment could improve the 
prognosis [7,8]. 
Since 1992, we have used a global strategy for the 
management of IPA in hematological patients. This approach 
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includes the following: (1) early, high resolution thoracic C T  
scanning; (2) systematic screening of Aspergillus antigen in 
serum and broncho-alveolar lavage (BAL) and plasma fibrino- 
gen concentration; (3) early initiation of antifungal treatment, 
combined with aggressive pulmonary surgery if necessary. 
Here, we present the results of t h s  approach, which has 
dramatically improved the prognosis for IPA in our neutro- 
penic patients [9,10]. 
PATIENTS 
Between January 1988 and July 2000, we managed 1579 
episodes of bone marrow aplasia in patients with hematolog4 
diseases. The clinical approach and management of febrile 
neutropenia during this period was essentially unchanged. 
Microbiological monitoring included a daily blood culture and 
samples from the throat, nose, urine and stool twice weekly. 
Axillary temperature was measured every 3 h. When the first 
febrile episode occurred, a beta-Iactam antibiotic plus 
aminoglycoside were used as empirical therapy after micro- 
biological sampling and a chest X-ray. When fever persisted, a 
glycopeptide was added at 48 h. AmB was administered (0.7- 
1 .O mg/kg per day) if the fever persisted for 24-48 h following 
the addition of glycopeptide or in the case of a subsequent 
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febrde episode in a patient with ongoing neutropenia. Since 
1992, in addition to this clinical strategy, we have made a 
systematic search for IPA in our neutropenic patients. 
A pneumonia was identified in 279 cases. A diagnosis of IPA 
was made in 86 patients (mean age, 53 & 17 years; male/ 
female ratio, 1.26). As in other reports, most patients (84%) 
had acute leukemia and the incidence of IPA was 5.5% 
[2,3,11,12]. Seven patients had a multiple myeloma, as 
previously reported [13]. As described by Gerson, the main 
risk factor of IPA occurrence was the length and severity of 
neutropenia [14]. In our series, all but one of the patients were 
neutropenic at the time of IPA diagnosis and the median 
duration of previous neutropenia (PMN < 100/mm3) was 19 
days (range, 8-43). The other risk factors were identified 
either as T-cell depletion in two d o  BMT patients or 
progressive hematological disease in 52% of our patients 
[5,11,12,15]. Because 90% of IPA occurred in patients 
hospitalized in rooms not protected by laminar airflow, the 
effect of air filtration on preventing aspergdlosis during 
neutropenia was good but not perfect [5,16]. 
CLINICAL SIGNS OF IPA 
Fever is too common a problem in neutropenic patients and 
should not be considered as an inmcator of aspergillosis [17]. 
However, in our experience, 87% of the patients who 
developed IPA had fever above 39 "C in the days before 
IPA diagnosis. The other recognized clinical indicators of IPA 
are chest pain and hemoptysis [18,19]. We observed these 
inmcators with a fiequency of 64% and 36%, respectively. 
VALUE OF THORACIC CT SCAN FOR IPA DIAGNOSIS 
Thoracic CT signs of IPA in neutropenic patients 
In neutropenic patients, thoracic CT scanning is an important 
tool for the hagnosis of IPA. Two CT signs have been clearly 
identified as inhcators of IPA. The CT halo sign (Figure 1) is 
described as a mass-like infiltrate with a surrounding halo of 
ground glass attenuation. It corresponds to a central fungal 
nodule surrounded by a rim of hemorrhage and coagulative 
necrosis [20]. Initially, the value of the CT halo sign as an 
indicator of IPA was described by Kuhlman et al. [21,22]. 
According to these preliminary results, numerous authors have 
acknowledged the value of the C T  halo sign as a sign highly 
predictive of IPA in neutropenic patients [23-251. The air- 
crescent sign (Figure 2) is described as a pulmonary cavitation. 
It is a later sign that appears with the bone marrow recovery 
[25,26]. This air-crescent sign is not pathognomonic of 
aspergdlosis but, in the case of patients with hematological 
malignancies, it is hghly suggestive of filamentous fungal 
Figure 1 CT halo sign. In the setting of prolonged neutropenia. the 
ground glass attenuation surrounding the nodule is considered as a 
typical halo sign and the diagnosis of IPA must highly considered. 
disease [26,27]. Therefore, we assigned major diagnostic 
importance to C T  scans and, in particular, to the halo sign. 
Thus, the occurrence of a febrile episode (most often a new 
episode in patients receiving broad-spectrum antibiotics) or 
the identification of a chest X-ray infiltrate during prolonged 
neutropenia (usually > 2 weeks) called for a CT scan. A high- 
resolution C T  scan was used with 10-mm-thick sections and 
admtional thin (1-mm) sections through any suspected fungal 
lesions. Contrast enhancement was used when the asperghry 
lesion threatened a pulmonary vessel. 
Impact of systematic use of CT scan in neutropenic patients 
Since 1992, we have successfully used thoracic C T  scanning 
in the management of febrile neutropenic patients [9]. 
Figure 2 CT air-crescent sign. When marrow recovery occurs, an air- 
crescent sign appeared on the CT scan, owing to detection of 
aspergillary lesions by PMN. A surgical resection could be indicated 
if aspergillosis is located near a pulmonary artery due to risk a massive 
hemoptysis by arterial perforation. 
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Before 1992, 13 cases of IPA were diagnosed and chest CT 
scans were used only to document aspergdlosis in eight 
patients (most oflen, after the diagnosis of IPA was made by 
other methods). In only one of the eight patients, the CT scan 
was the first evidence of IPA (with the presence of the halo 
sign). Since 1992, all the 73 remaining patients had at least one 
CT scan. Among these later patients, an early diagnosis of IPA 
(with evidence of the CT halo sign) was achieved in 68 
patients (93%). An earlier diagnosis of IPA was the result of 
their approach (Table 1). The median time between the first 
clinical sign and IPA diagnosis (retrospectively determined on 
fever, cough or chest pain occurrences) was significantly 
shortened &om 9 days (range, 0-17) before 1992 to 1 day 
(range, 0-5) since 1992 (P= 0.0001; Mann-Whimey U-test). 
During the same time, we have observed a reduction in IPA- 
related mortality from 54% to 18% (P= 0.008; Fisher's exact 
test) (Table 1 and Figure 3). 
Evolution of CT images during IPA in neutropenic patients 
To assess the value of thoracic CT scans in IPA diagnosis, we 
have retrospectively analyzed 71 sequential thoracic C T  scans 
in 25 neutropenic patients with surgically proven IPA [28]. 
Ths study demonstrated that, in a neutropenic patient at risk 
for invasive aspergdlosis (at least 2 weeks of deep neutropenia), 
the evolution of the IPA lesions could be observed over a 3- 
week period. In the first week, the halo sign is present, while 
the second week usually exhibits nonspecific changes (Table 
2). In the third week, the air-crescent sign appears and may be 
helpful as a late indicator of IPA. The major point of these 
observations is that the duration of the halo sign is short (less 
than 5 days in most cases). Therefore, to be useful for IPA 
diagnosis, the C T  scan must be performed very early in the 
course of the disease. 
Our experience is based exclusively on patients undergoing 
chemotherapies for leukemia without allogenic BMT. It 
agrees with the work of Blum et al., who described a 100% 
100% 
50% L Before 1992 
] P = 0.001 (Log Rank test) 0 .  
0 60 120 181) 
Days after IPA diagnosis 
Figure 3 Impact of early diagnosis of IPA on the outcome. Kaplan- 
Meier survival curves according to the strategy for IPA diagnosis and 
therapy. Since 1992, progress in early diagnosis (e.g. CT scan, 
AspergiNus antigenemia detection) combined with a medical-surgical 
approach were associated with improved survival of IPA patients. 
specificity rate and a 72% sensitivity rate of the halo sign when 
CT scans were performed in the first 2 weeks of the disease 
[24]. In allogeneic BMT patients, aspergdosis most often 
occurs after bone marrow engraftment, probably secondary to 
severe immunosuppression [29,30]. In the case of allogenic 
BMT, Ribaud reported an incidence of 60% of the halo sign 
in IPA in patients who had a CT scan [30]. However, some 
authors question the value of the halo sign as an important 
indicator of IPA [31,32]. In the report of Primak et aL, four of 
12 patients with the CT halo sign did not have any pulmonary 
infection [31]. However, these four patients were not 
immunocompromised. Overall, we think that the systematic 
use of thoracic CT scans is the best way to achieve an early 
diagnosis in neutropenic patients. 
BIOLOGICAL DIAGNOSIS OF IPA 
Detection of Aspergillus antigenemia 
Two tests are currently available for the detection of 
circulating galactomannan. In neutropenic patients, the latex 
Table 1 Contribution of CT-scans, Aspergillus antigenemia detection and surgery for the management of IPA in neutropenic patients 
Before 1992 Since 1992 P-value 
IPA observed (n )  13 73 NA 
Patients with thoracic CT scans (n )  8/13 (62%) 73/73 (100%) <0.0001** 
CT scan with suggestive halo-sign before 118 (13%) 68/73 (93%) 10.0001" 
IPA diagnosis (n )  
Prospective detection of Aspergillus antigenemia with an ELISA test 0113 (0%) 35/73 (48%) 0.0005" 
Pulmonary surgery combined with medical treatment 0/13 (0%) 26/73 (36%) 0.006'" 
Mean time 
Admission to hospital-IPA diagnosis (days) 31 + 8  21 * 5 0.0005' 
First IPA signs-I PA diagnosis (days) 7.4 L- 5 1.6 k 1.3 0.0001 * 
Death attributed to IPA ( n )  711 3 (54%) 13/73 (18%) 0.008"' 
IPA, invasive pulmonary aspergillosis; NA, not applicable. 'Mann-Whitney U-test; "Fisher's exact test. 
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Table 2 Characteristics of 71 sequential thoracic CT scans in 25 patients with surgically proven IPA 
Day 0 Day 3 Day 7 
~~ 
Day 14 
Median time after IPA diagnosis (days and range) 0 (0-0) 
Number of CT scans performed 
Patients with typicai thoracic CT halo signs 
Patients with low or nonspecific thoracic CT images 
Patients with typical thoracic CT air-crescent signs 
Median calculated volume of aspergillary lesions (cm3) 
24 
24/24 (1 00%) 
None 
None 
11 (0.1-57) 
Median number of circulating PMN/mm3 0 (0-200) 
3 (2-5) 
13 
8/13 (68%) 
4/13 (31%) 
1/11 (8%) 
0 (0-1600) 
37 (9-119) 
7 (6-10) 
18 
4/18 (22%) 
9/18 (50%) 
5/18 (28%) 
930 (0-13800) 
47 (4-167) 
14 (11-19) 
16 
3/16 (19%) 
3/16 (1 8%) 
10/16 (63%) 
2850 (0-1 1000) 
34 (2-202) 
IPA, invasive pulmonary aspergillosis. 
agglutination test (Pastorex Asperflus, Sanofi Diagnostics 
Pasteur, France) appears to be highly specific but not very 
sensitive [5,33]. In our experience, about one-thud of patients 
with IPA tested by Pastorex Aspergillus; were positive [34]. 
However, the test was never positive before IPA diagnosis. 
The use of the sandwich ELISA test (Platelia Asperflus'; 
Sanofi Diagnostics Pasteur, France) increases the sensitivity 
(about 15-20-fold) of Aspergillus antigenemia but is not perfect 
[5,33]. In a prospective multicenter study (using twice-weekly 
detection of antigenemia in neutropenic patients at risk for 
IPA), we have found the sensitivity and specificity of the 
ELISA test to be 50% and 97% respectively [35]. In the same 
study, the positive and negative predictive values were 60% 
and 80%, respectively, and one-third of the patients had a 
positive antigen test before the diagnosis of IPA by CT 
scanning [35]. 
Interest o f  BAL 
Fiberoptic bronchoscopy with BAL should be performed if' 
IPA is suspected. However, the level of positivity of hrect 
examination and culture does not exceed 30-50% [5,6,36]. In 
neutropenic patients, the combination of a positive culture of 
BAL for Aspergillus and the presence of new pulmonary 
infiltrates are tantamount to a confirmed diagnosis ofIPA [37]. 
In our treatements, 74 of 86 patients with IPA underwent a 
BAL. Direct examination and/or culture were positive in 46% 
of cases. Conversely, we found that the detection of Aspegilluj 
antigen on BAL supernatant with the Pastorex Asperflus' 
test was useful (42/59 positive results). Moreover, in 42 IPA 
patients with positive detection of Aspergillus antigen on BAL 
fluid, 20 had a negative culture for Aspergillus. To assess the 
value of detection of Aspergillus antigen on BAL, we 
conducted a prospective study on 139 consecutive BAL 
performed on patients with ( n = 6 1 )  or without (n=78) 
hematological malignancies. Among the nonhematologcal 
patients, no false-positive result was found. In the hematolo- 
gcal patients, the sensitivity and specificity of the test were 
67% and 89% respectively [38]. Therefore, in a febnle 
neutropenic patient with X-ray infiltrates or suggestive CT 
signs, the positivity of Aspergillus antigen in the BAL fluid 
could have the same value as the isolation of Aspergillus in the 
BAL. The isolation of Aspergillus in expectorated sputum or 
from a nasal swab should be taken into account when 
diagnosing aspergdosis in leukemic patients [39]. In our 
experience, the magnosis of IPA was most often established 
when positive results were available. 
Value of fibrinogen level 
In our neutropenic patients, the fibrinogen level is system- 
atically measured on alternate days during hospitalization. In 
our 86 IPA patients, fibrinogen increased from a meman value 
of 4.5 (range, 1.8-8.1) at day-10 before IPA diagnosis to a 
median value of 7 g/L (range, 4-11.4) at the day of IPA 
magnosis (mostly with the CT halo sign). In the setting of 
prolonged neutropenia, the fibrinogen value was also a 
prognostic factor, because a fibrinogen value higher than 9 
g/L was associated with a negative outcome. Specific receptors 
for fibrinogen have been identified on the surface of A.  
fumigatus conidia and they could act as mediators of conidial 
adherence to host tissue [40]. However, it remains impossible 
to know whether fibrinogen increase is the cause or the 
consequence of the progression of IPA. 
LEVEL OF CONFIDENCE OF 1PA DIAGNOSIS (TABLE 3) 
Definite and highly probable diagnosis of IPA 
Historically, a definite diagnosis of IPA required hstopatho- 
logical evidence of tissue invasion with hyphae niorpholog- 
cally consistent with Aspergillus species [6]. Using this 
definition, a positive culture was not necessary. In our 
experience, 36 patients had histologically proven IPA. 
Considering the hlgh value of CT halo or air-crescent signs 
in neutropenic patients, we thlnk that the combination of 
positive CT signs and either a positive culture of BAL or 
positive detection of Aspegillus antigen on BAL should also be 
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Table 3 Level of confidence of IPA diagnosis in neutropenic patients 
Definite Highly Probable 
I PA probable IPA I PA 
Possible 
I PA 
Positive tissue biopsy 
Positive direct examination or culture of BAL 
or positive Aspergillus antigen on BAL 
(with Latex agglutination test) 
Positive Aspergillus antigenemia 
(ELISA test 1.5 ng/mL) 
Typical thoracic CT halo or air-crescent signs 
I PA, invasive pulmonary aspeguillosis; BAL, broncho-alveolar lavage. 
considered as definite IPA. In our series, 35 patients exhbited 
such criteria for IPA. Clinical, ra&ologcal and serologcal 
features of these later patients did not differ from those with 
histologically proven IPA. Overall, 71 of 86 IPA cases (83%) 
were considered as definite. 
Probable or possible diagnosis of IPA 
Among the remaining neutropenic patients at risk for IPA 
(neutropenia = 10-15 days), we classified aspergillosis as 
probable or possible. A probable diagnosis of IPA required 
(in addition to appropriate clinical features) the presence of the 
C T  halo sign combined with the detection of circulating 
galactomannan (=1.5 ng/mL) with the ELISA test (Platelia 
Aspergdlus@'). A possible dlagnosis of IPA was only based on 
the presence of the C T  halo sign. Nine patients exhibited 
criteria for probable and six for possible IPA. The comparison 
of the sequential evolution of C T  images (with initial evidence 
of CT halo signs and secondary occurrence of CT air-crescent 
signs) between the definite or highly probable IPA and 
probable or possible IPA did not show any differences. The 
sequence of halo then air-crescent signs was observed in 42 of 
66 cases in the first group vs. 10 of 15 in the second group 
(P= 0.23; Fisher's exact test). 
MEDICAL ANTIFUNGAL TREATMENT OF IPA 
The traditional treatment of aspergdosis in immunocompro- 
mised patients is And3 [4-61. In leukemic patients, especially 
in allogenic BMT patients, the efficacy of And3 was limited, 
with a failure rate ranging &om 50% to 90% [4,5]. The recent 
introduction of new triazole agents (itraconazole or vorico- 
nazole) or new formulations of Aml3 (amphotericin B lipid 
complex, amphotericin B colloidal dispersion or liposomal 
amphotericin B) appears to improve the prognosis of 
pulmonary aspergillosis in hematological patients. The re- 
sponse rate with these newer drugs is reaching about 50% [41- 
481. In our experience, therapy mainly relied on these 
avdable drugs. Among our 86 IPA patients, 32 were treated 
with a single agent: itraconazole, 19 cases; voriconazole, eight 
cases; A d ,  five cases. Thrty-nine received a combination of 
two antifungal agents: A d  and itraconazole, 28 cases; lipidic 
formulations of AmB and itraconazole, 11 cases. The 
remaining 15 patients were treated with an AmB preparation, 
followed by an azole. The efficacy of these different 
approaches was globally similar (with a 77% success rate). 
The median duration of antifungal therapy was approximately 
6 months for the respondmg patients. 
SURGICAL MANAGEMENT OF IPA 
The surgcal procedures and inmcations for surgery have been 
partially described in previous reports [10,11]. Briefly, the 
indications for pulmonary surgcal resection of a suspected 
aspergdlary lesion are as follows: (1) prevention of massive 
hemoptysis when IPA threatened integrity of pulmonary 
artery; (2) surgical reduction of a remaining Aspmgilfus mass 
before a new myeloablative treatment; (3)  open lung tissue 
biopsy to confirm the IPA diagnosis. 
In immunocompromised patients with IPA, and especially 
in neutropenic patients, massive hemoptysis represents a 10- 
15% cause of death 1491. The angotropism ofhpergillus could 
explain the mechanism of hemoptysis. During the neutropenic 
period, following chemotherapy, the hyphae colonize the 
bronchi and the arteries, and cause local infarction [50]. When 
marrow recovery occurs, the granulocyte count increases and 
proteolytic enzymes are released from leukocytes at the site of 
aspergillary infection. This might cause destruction of lung 
tissue 1511. In the setting of IPA located near a pulmonary 
artery (or its dividing branches), it might cause massive 
hemoptysis by arterial perforation. Therefore, the recovery of 
the granulocyte count is a critical period [19,49]. In our 
experience, three of 13 neutropenic patients with IPA 
(observed before 1992) presented with severe hemoptysis 
when marrow recovery occurred. Two patients died, while 
one underwent successful bronchial arteria embolization. 
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Therefore, when IPA threatened the integrity of the more than 100 days after IPA hagnosis vs. 82% since this date; 
pulmonary artery, we hypothesized that preventive surgcal Figure 3). 
resection of the fungal lesion (before bone marrow recovery) In addition, in a univariate analysis model (log-rank test), 
might reduce the risk of death related to arterial perforation. In we have found several sipficant factors associated with a 
our institution, 14 patients underwent emergency pulmonary better prognosis: 
resection (despite persistent granulocytopenia and thrombo- 
cytopenia in 10 and 11 cases respectively) to prevent life- 
threatening hemoptysis. The need for surglcal intervention 
was based on the observation of repeated chest CT scans 
showing pulmonary aspergillosis that was in immediate 
proximity to the pulmonary artery (Figure 2). A lobectomy 
was performed in all but one case. 
Delayed surgery could be helpful in facilitating the 
improvement of IPA, as others have described [52-541. 
0 the achievement of a complete heniatological response with 
recovery of neutropenia ( P  < 0.0001); 
0 the occurrence of an air-crescent sign on CT scanning, 
which follows marrow recovery ( P  < 0.0001); 
0 a maximum fibrinogen level of < 9 g/L in the 10 days after 
IPA diagnosis (P  < 0.0001); 
0 initial unilateral involvement of the lung by IPA (P= 0.02); 
combined surgical and mehcal therapy ( P ~ 0 . 0 5 ) ;  
Resection surgery decreases the volume of the remaming In an multivariate analysis (Cox model), three poor 
aspergdlary mass. In the case of single aspergdlary foci, it could prognostic factors were found to be significant (Figure 4): 
be curative. In this later case, it facilitates the further 
myeloablative therapies and, in particular, subsequent allogenic 
BMT [52,53]. We have carried out delayed elective surgery in 
12 patients. Seven patients underwent surgical resection of a 
pulmonary residual mass before the next course of hemato- 
logical treatment, while surgery was undertaken as a diagnostic 
procedure in five patients. 
Overall, among our 26 surglcal patients, the main criteria of 
IPA diagnosis before surgery were based on CT findings (alone 
or combined with antigen test on BAL fluid) in 81% of cases. A 
definite diagnosis of IPA was achieved histologically in all these 
patients. Moreover, the analysis of sequential thoracic CT scans 
performed before surgery (Table 2) showed that the volume of 
the aspergillary lesions typically increased 3-4-fold in the first 
week ofthe disease [28]. Despite this initial apparent failure, we 
achteved an 84% rate of success in the treatment of IPA with 
this surgcal approach [28]. Therefore, in a medical-surglcal 
approach, the initial radiological progression of the disease is 
not usually correlated with the prognosis. 
OUTCOME AND PROGNOSTIC FACTORS 
In our experience, 66 of 86 (77%) neutropenic patients with 
IPA were improved or cured. Currently, the mehan survival 
of respondmg patients is 393 days after IPA diagnosis (range, 
103-3683). These results seem to be superior to other reports 
of IPA treatment which mainly relied on a medical approach 
Since 1992, we have initiated a systematic and global strategy 
of IPA management in neutropenic patients. The main results 
of this diagnostic and therapeutic strategy were a reduction in 
the time required for diagnosis (more than 1 week since 1988) 
and an improvement in the rate of survival. The effect of an 
earlier diagnosis of IPA was associated with a better prognosis 
of the disease (46% of patients observed before 1992 survived 
[4,37,41-481. 
0 a fibrinogen level=9 g/L during the 10 days after IPA 
diagnosis (P' 0.003); 
0 the absence of the CT air-crescent sign during IPA 
evolution (P= 0.0004); 
0 initial bilateral involvement of the lung by IPA ( P = O . O l ) .  
CONCLUSION 
Although pulmonary aspergillosis in neutropenic patients 
remains a life-threatening complication of myeloablative 
therapy, a global strategy €or diagnosis and therapy could 
greatly improve its prognosis. Early IPA diagnosis could be 
achieved with careful daily clinical monitoring, systematic use 
of CT scans, detection of Arpergillus antigenemia (and plasma 
fibrinogen level) and detection of Aspergillus antigen on BAL 
fluid (in adhtion to culture). The main goal of this diagnostic 
strategy is to initiate antifungal treatment as soon as possible. 
0 or 1 factor 
l W % I t  
P < 0.0001 (Log Rank test) 
0 .  
0 60 120 180 
Days after IPA diagnosis 
Figure 4 Impact of IPA prognostic factors on the outcome Kaplan- 
Meier survival curves according to the presence of three independent 
factors (fibrinogen level = 9 g/L during the 10 days after IPA 
diagnosis, absence of CT air-crescent sign during IPA evolution and 
initial bilateral involvement of the lung by IPA) 
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Moreover, a surgical approach should be considered if 
necessary (either as an emergency procedure to prevent a 
massive hemoptysis before marrow recovery or as an elective 
procedure after neutropenia resolution). Nevertheless, the 
control of underlying hematological hsease remains one of the 
factors for improvement. 
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